Outburst! Starbucks announced its withdrawal, and the "truth" about the injury of the US nuclear submarine South China Sea was announced! The 70 billion new crown oral drug giant suddenly collapsed, why did it become a bearish?

In times of conflict, business giants also seem powerless!

On May 23, local time, the official website of Starbucks announced that it would withdraw from the Russian market and no longer retain the brand in the Russian market, ending 15 years of operation. Starbucks also said in the announcement that it will continue to pay nearly 2,000 Russian employees for a six-month salary and help them find new jobs.

This is another business giant after McDonald's that has withdrawn from the Russian market. It can be expected that more large companies may exit Russia in the future. A countercurrent is emerging. After this countercurrent, there will undoubtedly be a contraction of the market, the economy, and globalization. Reflected in the stock market, it naturally becomes a large bearish. This morning, the US stock futures index once again killed, the A-share market performance is also relatively weak, as of the morning close, the main index all-round killed.

In particular, it is worth mentioning that Junshi Bio, with a market value of nearly 70 billion yuan. The company last night disclosed the blockbuster benefits of the new crown special drug. However, after opening slightly higher this morning, the stock suddenly fell sharply, with the biggest decline in the morning at one point exceeding 16%, and Hong Kong stocks were also taken down. And netizens said bluntly: the main force has taught retail investors a lesson fiercely!

So, what's going on? What does this mean for the market as a whole?

Starbucks evacuation

According to the news of China Youth Network, on May 23, local time, the official website of Starbucks issued an announcement announcing that it would withdraw from the Russian market and no longer retain the brand in the Russian market, ending 15 years of operation.

Starbucks also said in the announcement that it will continue to pay nearly 2,000 Russian employees for a six-month salary and help them find new jobs.

It is reported that Starbucks has 130 stores in Russia, all of which are franchisees, and Starbucks is not responsible for operating these stores. According to the U.S. Consumer News and Business Channel (CNBC), the Russian business accounts for less than 1% of Starbucks' total revenue.

The news of Starbucks' announcement of its withdrawal quickly rushed to the number one position in Weibo's hot search. This means that the Chinese people are still quite concerned about this matter.

In fact, as early as March 8 this year, Starbucks CEO Kevin Johnson said: "We have decided to suspend all commercial activities in Russia, including the shipment of all Starbucks products." In addition, McDonald's, Coca-Cola, and PepsiCo also announced the suspension of operations in Russia at that time.

On May 16, local time, McDonald's issued an announcement that it finally decided to withdraw from the Russian market and is seeking to sell all of its McDonald's restaurants in Russia to local buyers. At the same time, McDonald's also said that it will continue to retain its trademark in Russia, but existing stores will no longer use McDonald's name, logo, brand and menu.

However, the Russian version of McDonald's may also be available soon. On May 19, McDonald's agreed to sell its Russian operations to current franchise holder, Siberian businessman Alexander Govor. Under the agreement, Govor will acquire all of McDonald's' stores and operate under the new brand.

In addition, on May 16, Russian beverage producer Ochakovo also launched a new series of soft drinks to replace the iconic brand Coca-Cola that left the Russian market.

Junshi Creatures collapsed in the good

Back to the A-share market, the most surprising thing is the killing of Junshi Bio. The stock fell more than 16% in early trading. But A-shares opened up nearly 2 percent, and H-shares opened up nearly 5 percent.

In fact, last night, Junshi Bio was favorable to happen. Junshi Bio announced on the evening of May 23 that its holding subsidiary Juntuo Biotech and Wangshan Wangshui cooperated to develop oral nucleoside anti-SARSCoV-2 drug VV116 tablets (hereinafter referred to as "VV116") in a phase III registered clinical study (NCT05341609) compared to nematvir tablets/ritonavir tablets (i.e., PAXLOVID) for the early treatment of mild and moderate novel coronavirus pneumonia ("COVID-19") to achieve the main endpoint of the protocol. The Company will communicate with the regulatory authorities in the near future to submit a new drug listing application.

Some professionals believe that this is only the announcement of the main end point, and the complete data will be released more formally on subsequent appropriate occasions. At present, the data fully supports the declaration, and the company will communicate with the drug regulatory authorities in the near future to submit a new drug listing application.

Secondary endpoint metrics are seen again in the full data. But the company's primary endpoint, "sustained clinical recovery," is that all COVID-19-related target symptom scores = 0 points for 2 consecutive days were met, with the head-to-head primary endpoint being met, and secondary endpoints including "percentage of subjects who progressed to COVID-19 progression (defined as progression to severe/critical COVID-19 or all-cause death) as of day 28" are unlikely to be met.

Under prudent assumptions, it is expected that the domestic pricing will be 500 yuan / person, the first year of sales of 20 million courses, sales exceeded 10 billion, the second year of sales of 40 million courses, the peak reached more than 20 billion, the project DCF value of more than 70 billion, but this does not take into account the government's procurement and advance preparation and overseas markets. "The reality will far exceed our assumptions." The professional said.

Logically, the significant progress of the new crown oral drug is a heavy positive for both the company itself and the entire market. So, why did the benefits of Junshi creatures become negative? Some market participants believe that there may be flaws in the clinical trials of Junshi Biology.

The report of the US nuclear submarine hitting the mountain in the South China Sea was released

According to the news of overseas networks on May 24, CNN and other US media reported that on the 23rd local time, the US Navy announced the final investigation report of the "Connecticut" nuclear submarine "hitting the mountain" accident in the South China Sea in 2021. The report pointed out that the cause of the accident was related to errors in navigation planning and risk management, resulting in the injury of 11 sailors and the long-term inability of the submarine to operate.

The report mentions that the October 2021 accident "was caused by the accumulation of errors and omissions in navigation planning, risk management, etc." The execution process is far from meeting U.S. Navy standards." Eleven sailors were injured in the accident, the most serious of which were scalp lacerations and fractures of the shoulder blades. Due to the constant damage caused by the stranding process, the Connecticut nuclear submarine was unable to operate for a long time.

Us media also said that after the incident, the US Navy dismissed the commander, deputy captain and chief sonar technician of the "Connecticut" submarine on the grounds of "losing confidence".

On November 5, 2021, Chinese Foreign Ministry spokesman Wang Wenbin urged the US side to stop sending warships and warplanes around to provoke and show off force, and to stop harming the sovereignty and security of other countries, otherwise such accidents may not be less, but more.

Editor-in-charge: Tactical Constant